Regeneron's Eylea drug has phase III data available for DME, the same indication that Iluvien is seeking FDA approval for. This is an excerpt from the data release. FIVE monthly eye injections in a row, then, every two months after that? Wow, sign me up or go blind. Funny, Paul Ashton will be at the bio better conference next week. He'll present and the title will be "A SIMPLE ROUTE TO BIO-BETTERS". Now, the world might find that there is one, PSDV's Tethadur!
In the VIVID-DME trial, after one year patients receiving EYLEA 2 mg monthly had a mean change from baseline in BCVA of 10.5 letters (p
in hearing this, I'm not too happy that there is a competitor to lluvien in PH III, concern being that will be in the backs of FDA's mind on lluvien PDUFA date...... to me the most important thing by far right now is Oct 17th....hoping for the best........
GS, It's an important date, obviously, and important for PSDV's pocketbook. But, as PSDV is all about technology, the best of our technology is on display in the UK on Tuesday and Wednesday, with the big pharma's of the world listening. How many companies are claiming the ability to deliver biologics, in a pharma world worth many trillions of dollars........ONE.....PSDV, oh right now our MC is 118M. Fairly favorable math indeed.